Latest news with #radiopharmaceuticals
Yahoo
27-07-2025
- Business
- Yahoo
Lantheus Holdings Expands Alzheimer's Diagnostics Despite Recent Stock Dip
Lantheus Holdings, Inc. (NASDAQ:LNTH) is one of the . The company completes the acquisition of Life Molecular Imaging Limited amid a fall in the monthly and weekly performance of shares. A medical professional performing a pulmonary function assessment on a patient. Lantheus Holdings, Inc. (NASDAQ:LNTH) is a Massachusetts-based company specializing in radiopharmaceuticals and diagnostic imaging. Through Lantheus Medical Imaging, Progenics, and EXINI, the company develops and commercializes precision diagnostics and radiotherapeutics used in oncology and cardiology. It is supported by strategic partnerships from global healthcare leaders. On July 21, 2025, Lantheus Holdings, Inc. (NASDAQ:LNTH) announced the completion of the acquisition of Life Molecular Imaging Limited. With the $350 million acquisition and the addition of Neuraceq, an F-18 PET imaging agent, Lantheus Holdings, Inc. (NASDAQ:LNTH) increases its capabilities in Alzheimer's disease diagnostics. On the other hand, the company's weekly and monthly performance were down by 10.98% and 8.65%, respectively. These declines follow the expiration of the company's transitional pass-through payment status for its product PYLARIFY and the subsequent implementation of the mean unit cost pricing for Medicare fee-for-service coverage. However, analysts, including Truist Financial and TD Cowen, stick to their Buy rating on the stock, signaling confidence in the company's future growth. Lantheus Holdings, Inc. (NASDAQ:LNTH) is anticipated to incur an 8.36% EPS growth in the next 5 years, and it currently has a low beta of 0.15, which makes the stock a good buy for investors seeking long term stocks with low risks. While we acknowledge the potential of LNTH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Metal Stocks with Insider Buying in 2025 and 10 Energy Stocks with Insider Buying in 2025 Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Dr Oliver Sartor Appointed to Radiopharm Scientific Advisory Board
SYDNEY, July 22, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, 'Radiopharm' or the 'Company'), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce the appointment of Dr Oliver Sartor, MD to the Company's Scientific Advisory Board (SAB). Dr Sartor is an internationally recognised medical oncologist and scientist specialising in prostate cancer and radiopharmaceutical therapies. He currently serves as Director of Radiopharmaceutical Clinical Trials and Chair of the Genitourinary Cancer Disease Group at the world-renowned Mayo Clinic, in Rochester, Minnesota. He was previously Laborde Professor of Medicine and Urology and Medical Director of Tulane Cancer Center in New Orleans under Tulane University School of Medicine. Dr Sartor has also held senior roles at LSU Health Sciences Center, Dana‑Farber/Harvard Medical School, and as Medical Oncology Co‑Chair of the GU Committee of NRG Oncology. Dr Sartor received his MD with honours from Tulane University School of Medicine in 1982, completed internal medicine residency at Tulane, and a medical oncology fellowship at the National Cancer Institute (NCI). Since 1990 he has focused on prostate cancer clinical research, authoring more than 500 peer‑reviewed publications and leading multiple pivotal Phase 3 trials that resulted in FDA approvals for therapies including samarium‑153 EDTMP, cabazitaxel, radium‑223, and PSMA‑targeted radioligand therapy. 'Dr Sartor brings an unparalleled depth of expertise in both clinical translation and radiopharmaceutical therapies,' said Riccardo Canevari, Managing Director and CEO of Radiopharm Theranostics. 'We're very honoured to welcome him to our SAB. His insight and leadership will be invaluable as we advance our radiopharmaceutical pipeline.' About Radiopharm Theranostics Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and three Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. For more information: Investors:Riccardo CanevariCEO & Managing DirectorP: +1 862 309 0293E: rc@ Anne Marie Fields Precision AQ (Formerly Stern IR) E: Media:Matt WrightNWR CommunicationsP: +61 451 896 420E: matt@ Follow Radiopharm Theranostics: Website – Twitter – Linked In – –
Yahoo
11-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
10-07-2025
- Business
- Yahoo
Telix Pharmaceuticals (TLX) Announces That Gozellix® is Commercially Available
Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the The research firm stated that Telix Pharmaceuticals Limited (NASDAQ:TLX) is the most diversified, comprehensively positioned, and standalone publicly-traded radiopharmaceuticals company. The firm also cited the commercial-stage portfolio of targeted radiotherapy agents catering to the unmet needs in oncology. The company announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), is commercially available nationally in the US. A robotic arm picking up a product assembly line, displaying the company's consumer healthcare and wellness offerings. Telix Pharmaceuticals Limited (NASDAQ:TLX) highlighted that Gozellix builds on proven diagnostic excellence to offer early and accurate detection of metastases at initial staging, with 90% specificity. Telix Pharmaceuticals Limited (NASDAQ:TLX) remains focused on innovation in PSMA imaging, and Gozellix was the result of this commitment. It provides a new level of flexibility in distribution, production, and scheduling, together with a high standard of service and reliability. Notably, PSMA-PET imaging has been established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. That being said, only a relatively small fraction of 3.4 million men having prostate cancer in the US benefited, mainly due to access and availability challenges. Gozellix's enhanced formulation provides a greater level of patient access as well as convenience via an extended transportation distance and clinical administration window. Telix Pharmaceuticals Limited (NASDAQ:TLX)'s stock has a consensus price objective of $22.92. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now Disclosure: None. This article is originally published at Insider Monkey. 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
09-07-2025
- Business
- Yahoo
Actithera draws new investors to radiopharma drug pitch
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Actithera, a radiopharmaceutical drugmaker based in Oslo, Norway and Cambridge, Massachusetts, has raised just under $76 million in Series A venture financing to build out its cancer drug pipeline. In a Wednesday statement, the biotechnology company said it would use the new funds to advance into clinical development an experimental treatment targeting what are known as fibroblast activation proteins. M Ventures, which helped found the company in 2021, co-led the Series A round with Hadean Ventures, Sofinnova Partners and 4BIO Capital. Five other firms also participated. Radiopharmaceuticals offer a better way to target tumor-killing radiation more precisely to cancerous cells and, accordingly, they've drawn rising interest from drugmakers. The technology works by attaching a radioisotope to a targeting compound via a specially engineered 'linker' molecule. While radiopharmaceuticals have been around for years — Bayer's Xofigo was approved in the U.S. in 2013 — the field has taken off since the success of Novartis' prostate cancer treatment Pluvicto. The drug earned Novartis more than $1.3 billion in 2025, giving the industry a glimpse of radiopharmaceuticals' sales potential. Other large companies, like Bristol Myers Squibb and Eli Lilly, have entered the field with acquisitions of earlier-stage public biotechs. Private radiopharma companies, meanwhile, drew more than $1.1 billion since 2022 from a group of 23 venture firms tracked by BioPharma Dive. Actithera is designing its cancer drugs so they can stay in a tumor for longer by binding tightly to proteins that help a tumor grow. Founded by Andreas Goutopoulos, a veteran of Merck KGaA's U.S. subsidiary EMD Serono Inc., the biotech is focused first on an enzyme called fibroblast activation protein, or FAP. The protein is expressed on cells that form connective tissue, but in cancer can support tumor growth. Actithera aims to eliminate those proteins and cancer-associated fibroblasts in 'a cross-fire effect that kills nearby tumor cells,' Goutopoulos said. 'It's a way to dismantle a critical barrier to immune and therapeutic access,' he wrote in an email to BioPharma Dive. Radiopharmaceuticals can be tricky to develop. Manufacturing is complex and expensive, and in response, companies like Novartis have opened dedicated production facilities. The isotope they contain also degrades over time, making the logistics of their delivery critical. Actithera is one of many up-and-coming biotechs looking to follow Novartis' lead. Some of those, including Novartis and Ratio Therapeutics, are also targeting FAP. Actithera has not disclosed which cancers it's targeting with its therapies. The company is 'preparing for clinical development in 2026' across multiple indications, Goutopoulos said. 'Actithera stands out as one of the most thoughtfully constructed radiopharma platforms we've seen, combining smart molecular design with a deep understanding of tumor biology and clinical need,' Roger Franklin, a partner at Hadean Ventures, said in a statement. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
